Barclays PLC Has $4.28 Million Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Barclays PLC reduced its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 9.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 633,125 shares of the company's stock after selling 64,307 shares during the period. Barclays PLC owned about 0.16% of Recursion Pharmaceuticals worth $4,281,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Recursion Pharmaceuticals by 40.1% in the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock worth $229,908,000 after buying an additional 9,737,196 shares in the last quarter. Geode Capital Management LLC grew its position in Recursion Pharmaceuticals by 12.1% in the fourth quarter. Geode Capital Management LLC now owns 6,087,149 shares of the company's stock valued at $41,160,000 after acquiring an additional 655,238 shares during the period. Norges Bank acquired a new position in Recursion Pharmaceuticals during the fourth quarter worth $23,429,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Recursion Pharmaceuticals by 17.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,274,003 shares of the company's stock valued at $15,372,000 after acquiring an additional 333,323 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in shares of Recursion Pharmaceuticals by 6.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,176,191 shares of the company's stock valued at $7,751,000 after purchasing an additional 67,464 shares in the last quarter. Institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Price Performance

Shares of Recursion Pharmaceuticals stock traded up $0.36 during midday trading on Friday, reaching $5.86. The company had a trading volume of 7,562,521 shares, compared to its average volume of 12,371,508. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a fifty day simple moving average of $5.87 and a 200 day simple moving average of $6.75. Recursion Pharmaceuticals, Inc. has a 1-year low of $3.79 and a 1-year high of $12.36. The company has a market capitalization of $2.35 billion, a price-to-earnings ratio of -3.82 and a beta of 1.00.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. During the same period last year, the business posted ($0.42) earnings per share. The firm's quarterly revenue was down 57.8% on a year-over-year basis. As a group, equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on RXRX. Leerink Partners dropped their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Morgan Stanley dropped their price objective on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. KeyCorp reduced their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, April 8th. Finally, Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $8.20.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.